REPL241220P22500
- 9.00
- 0.000.00%
Replimune Newsroom
Express News | Replimune Shares Extend Gains; Last up 8%
Express News | Replimune Group Inc - Amendment Reduces Atm Offering to $89 Mln
Express News | Replimune Group Inc - Co & Leerink Partners LLC Enters Amendment No. 2 to Sales Agreement
Reported Earlier, Replimune Prices $140M Upsized Public Offering Of 6,923,000 Common Shares At $13/Share
Replimune Expects Gross Proceeds From Offering to Be Approximately $140M>REPL
Replimune Announces Pricing of 6.9M Shares of Common Stock at $13.00 Each >REPL
Replimune Expects Offering to Close Nov. 27>REPL
Replimune Announces Pricing of Upsized Public Offering
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
Replimune Plans $125 Million Stock Sale, Net Proceeds to Fund Prospective Skin Cancer Treatment
Express News | Replimune Announces Proposed Public Offering
More Money In The Bank For Replimune Group Insiders Who Divested US$860k
Replimune REPL +35% BLA Submission; Omeros OMER +41% BLA Update
12 Health Care Stocks Moving In Friday's Pre-Market Session
Friday Market Climbs | Wall Street Today
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Dow Jumps 300 Points; Gap Posts Upbeat Earnings
Replimune Climbs After Updates on Lead Drug
Market-Moving News for November 22nd
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $18